Monotherapy

Other Medications

Description

This medication is a standard chemotherapy approach being studied in older adults (70 years and older) with metastatic colorectal cancer. The goal of the study is to see if starting with a lower dose of chemotherapy (dose-reduced) is as effective as starting with the full standard dose, while potentially causing fewer severe side effects. The study compares different chemotherapy regimens (single drug or combination) based on a patient's risk assessment for toxicity. The study aims to improve quality of life, reduce hospital visits, and maintain physical function in this age group. It is being evaluated in a large, Phase 3 clinical trial.

Mechanism of Action

This is a chemotherapy approach, meaning it uses drugs to kill cancer cells or stop them from growing. The specific drugs used (like fluoropyrimidines and oxaliplatin) are standard treatments for colorectal cancer. The study is investigating whether starting with a lower dose of these drugs is a safe and effective strategy for older patients who may be more sensitive to the side effects of full-dose chemotherapy.

Side Effects

As this is a chemotherapy approach Potential side effects are similar to those associated with standard chemotherapy regimens Which can include nausea Vomiting Diarrhea Fatigue Hair loss Mouth sores And increased risk of infection due to low blood cell counts. The study specifically aims to reduce the occurrence of severe (grade 3 or higher) side effects by using dose reduction upfront. The specific side effects experienced will depend on the individual drugs used and the dose received. The study is carefully monitoring side effects to compare the dose-reduced approach with the full-dose approach.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06275958 med_phase_prefix3
Recruiting
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
Netherlands